Kezar Life Sciences Acquired by Aurinia | Healthcare M&A Deal

Aurinia Pharmaceuticals Inc. has completed the acquisition of Kezar Life Sciences, a pharmaceuticals business in Delaware, for $6.955 per share in cash plus contingent value rights. Kezar Life Sciences develops oncology-focused therapeutics, and Aurinia acquisitions expand its healthcare M&A pipeline in DE acquisitions. The merger acquisition was structured as a strategic acquisition by Aurinia, using Aurinia Pharma U.S., Inc. and Aurinia Merger Sub, Inc. to purchase all issued and outstanding Kezar common stock. The healthcare deals DE transaction closed under a merger agreement dated March 30, 2026, with a total consideration amount reported as $6.955 and an additional $0.001 component.